*Department of Neurology and Massachusetts Alzheimer's Disease Research Center, Massachusetts General Hospital and Harvard Medical School, Boston
†The Massachusetts School of Professional Psychology, West Roxbury, MA
Reprints: Dr Alireza Atri, MD, PhD, Massachusetts General Hospital Memory Disorders Unit, 15 Parkman Street, WACC 715, Boston, MA 02114 (e-mail: [email protected]).
Supported by the National Institutes of Aging through grants 1K23 AG27171-01 (A.A.) and 5P50 AG05134 [J.H.G. and B.T.H.; Massachusetts Alzheimer's Disease Research Center (MADRC)], and the NIH Loan Repayment Program (A.A.).
Drs Atri, Locascio, and Growdon contributed to the design, and execution of the study, and the interpretation of the data. Ms Shaughnessy contributed to the collection, processing, presentation, and interpretation of the data. Drs Atri and Locascio were responsible for the statistical analyses and contributed to the interpretation of the data. All authors contributed to the writing of the manuscript.
Disclosure: Dr Atri has received remuneration for lectures or consulting from Eisai, Forest, Merck, and Pfizer, and investigator-initiated research grant support from Forest. He has also participated in conducting clinical trials in association with the Alzheimer's Disease Cooperative Study (ADCS), Elan, Neurochem, and Wyeth. There was no sponsorship or involvement by the pharmaceutical industry, including the motivation, design, execution, interpretation, presentation, and costs associated with any part of this study. Ms Shaughnessy, Dr Locascio, and Dr Growdon have no potential conflicts to disclose.
Received for publication June 21, 2007; accepted December 7, 2007
